Halozyme Therapeutics, Inc. $HALO Stock Holdings Lessened by Vestcor Inc

Vestcor Inc cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 21.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,512 shares of the biopharmaceutical company’s stock after selling 9,299 shares during the quarter. Vestcor Inc’s holdings in Halozyme Therapeutics were worth $2,255,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of HALO. Empowered Funds LLC purchased a new stake in shares of Halozyme Therapeutics during the first quarter valued at $755,000. Acadian Asset Management LLC purchased a new position in Halozyme Therapeutics in the 1st quarter worth about $195,000. Hsbc Holdings PLC raised its holdings in Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 5,448 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 174 shares during the period. Finally, Baird Financial Group Inc. lifted its stake in Halozyme Therapeutics by 6.2% during the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after buying an additional 650 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HALO has been the subject of several recent analyst reports. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. HC Wainwright raised their price objective on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. UBS Group reiterated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised Halozyme’s earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, signaling confidence in the company’s longer-term profit growth. Halozyme Therapeutics article
• Positive Sentiment: Analysts also increased estimates for several individual quarters in 2027, reinforcing a constructive earnings outlook for Halozyme Therapeutics. Halozyme Therapeutics article
• Neutral Sentiment: One near-term forecast was trimmed slightly and another was revised lower, but the overall analyst tone remains mostly favorable. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider selling by the CEO was disclosed, but the trades were executed under a pre-arranged trading plan, which typically lessens investor concern. Halozyme Therapeutics article

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $71.53 on Monday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The firm has a market capitalization of $8.48 billion, a price-to-earnings ratio of 25.73, a price-to-earnings-growth ratio of 0.30 and a beta of 0.88. The company has a 50 day simple moving average of $66.79 and a 200-day simple moving average of $68.72. Halozyme Therapeutics, Inc. has a 52-week low of $51.06 and a 52-week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same quarter in the prior year, the business earned $1.11 EPS. The company’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, COO Cortney Caudill sold 8,857 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total value of $599,087.48. Following the transaction, the chief operating officer owned 7,055 shares in the company, valued at $477,200.20. The trade was a 55.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $71.75, for a total value of $1,435,000.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $55,088,215. The trade was a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 102,107 shares of company stock valued at $6,898,834. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.